Jacobio Pharma
Jacobio Pharma is a biopharmaceutical company developing targeted cancer therapies against historically undruggable signaling proteins.
- 300
- Public company
- Beijing, CNChina
Jacobio Pharma is a biopharmaceutical company developing targeted cancer therapies against historically undruggable signaling proteins.
jacobiopharma.comCrawled Oct 16, 2026
Jacobio says its name combines “Jacob,” Hebrew for “to seize,” with “bio,” a root of “biopharmaceutical.” It says its brand mark symbolizes the World Health Organization’s health mission and that it aims to develop medicines and therapies.
Jacobio Pharma (1167.HK) has a pipeline targeting KRAS, tumor immunology, tumor metabolism, P53, RB, and MYC. Its laboratories are in Beijing and Shanghai, China, and Boston, USA; it has induced allosteric drug discovery and iADC development platforms.
Beijing Jacobio Pharmaceuticals Co., Ltd. says it collects personal information when needed or voluntarily submitted through the website, including names, contact details, education and employment information, and messages.
The terms state that access to Beijing Jacobio Pharmaceuticals Co., Ltd.’s website is subject to the stated conditions. Website content is for personal, non-commercial use, and users are expected to respect rights in the content and comply with applicable laws.
Jacobio Pharma licenses its pan-KRAS inhibitor JAB-23E73 to AstraZeneca under a global exclusive agreement. AstraZeneca receives exclusive development and commercialisation rights outside mainland China, while the companies jointly develop and commercialise the asset in mainland China; Jacobio receives US$100 million upfront and is eligible for up to US$1.915 billion in additional milestone payments, plus tiered royalties.
Dec 2025PRNewswireNews article
Jacobio Pharma presents pre-clinical data on its internally discovered pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The compound inhibits KRAS in both ON and OFF states, spares HRAS and NRAS, and shows antitumor activity across multiple KRAS-driven cancer models, tumor regression without significant body weight loss, and favorable oral pharmacokinetics; Phase I trials for advanced solid tumors with KRAS alterations are ongoing in China and the United States.
Oct 2025PRNewswireNews article
Jacobio Pharma licenses the China rights to its KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist Pharmaceuticals. Jacobio receives about RMB200 million near term, including RMB150 million upfront, plus potential milestone payments of up to RMB700 million and tiered double-digit royalties; JAB-3312 royalties can reach 20%. Allist takes responsibility for commercialization and subsequent clinical development costs in China, marking Jacobio’s entry into commercialization.
Aug 2024PRNewswireNews article
Jacobio Pharmaceuticals reports CNY486 million in 2020 revenue and more than CNY230 million in research and development spending in its first annual results since its Hong Kong listing; R&D spending is up 66% from 2019. Licensing out its SHP2 inhibitors generates revenue, while clinical-stage programs include KRAS G12C inhibitor JAB-21000 and BET inhibitor JAB-8263. The company is building a 20,000-square-meter GMP factory in Beijing and has about 180 employees, up from 130.
Mar 2021PRNewswireNews article